Dr. Damara Ortiz, MD
Claim this profileUPMC Children's Hospital of Pittsburgh
Studies Hunter Syndrome
Studies Mucopolysaccharidosis
7 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Damara Ortiz, MD is currently running
ELAPRASE + Prophylactic Therapy
for Hunter Syndrome
The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter syndrome. In this open label, single arm study, all participants will receive ELAPRASE treatment and a prophylactic ITR. Participants will be treated with ELAPRASE for up to 104 weeks. The prophylactic ITR will start 1 day prior to the start of ELAPRASE. The prophylactic ITR will consist of a 5-week cycle of: Rituximab (intravenously \[IV\], weekly for 4 weeks); Methotrexate (oral, 3 times per week for 5 weeks) and intravenous immunoglobulin (IVIG) (IV, every 4 weeks of the cycle). Following the completion of 1 cycle, an assessment will be made at Month 6, 12, and 18 regarding the need for administering another 5-week cycle of the ITR. Participants will be in the study for approximately 112 weeks (including 6 weeks for screening, up to 104 weeks for treatment, and 2 weeks for follow-up).
Recruiting3 awards Phase 48 criteria
AMT-191
for Fabry Disease
This is an open-label, multi-center study to evaluate safety, tolerability, and exploratory efficacy of a single dose of intravenously-administered AMT-191. The plan is to investigate 2 sequential dose cohorts with 3-6 Participants per cohort. Participants will continue receiving regularly scheduled enzyme replacement therapy (ERT) until they meet the criteria for withdrawal.
Recruiting1 award Phase 1 & 25 criteria
More about Damara Ortiz, MD
Clinical Trial Related2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Damara Ortiz, MD has experience with
- ELAPRASE
- Intravenous Immunoglobulin (IVIG)
- Methotrexate
- Rituximab
- FLT201
- Elaprase
Breakdown of trials Damara Ortiz, MD has run
Hunter Syndrome
Mucopolysaccharidosis
Postprandial Fullness Syndrome
Cerebroside Lipidosis Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Damara Ortiz, MD specialize in?
Damara Ortiz, MD focuses on Hunter Syndrome and Mucopolysaccharidosis. In particular, much of their work with Hunter Syndrome has involved IDS positive patients, or patients who are undergoing treatment.
Is Damara Ortiz, MD currently recruiting for clinical trials?
Yes, Damara Ortiz, MD is currently recruiting for 2 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Damara Ortiz, MD has studied deeply?
Yes, Damara Ortiz, MD has studied treatments such as ELAPRASE, Intravenous Immunoglobulin (IVIG), Methotrexate.
What is the best way to schedule an appointment with Damara Ortiz, MD?
Apply for one of the trials that Damara Ortiz, MD is conducting.
What is the office address of Damara Ortiz, MD?
The office of Damara Ortiz, MD is located at: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15224 United States. This is the address for their practice at the UPMC Children's Hospital of Pittsburgh.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.